Encouraging results were seen in an early-stage trial of ISIS-SMNRx, a drug designed to increase levels of a deficient protein in spinal muscular atrophy
New content is being added every day. Please check back again.
Muscular Dystrophy Association — USA National Office222 S. Riverside Plaza, Suite 1500Chicago, IL 60606(800) 572-1717
©2015, Muscular Dystrophy Association Inc. All rights reserved.